CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
New therapies in a publicly funded healthcare system are first appraised by health technology assessment agencies that provide funding recommendations to the payers. Treatment with Chimeric Antigen Receptor-T cell (CAR-T) therapy is revolutionizing the management of patients with relapsed/refractory...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2023-04-01
|
| Серія: | Current Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/1718-7729/30/4/305 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|